Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Patricia Clarkson plays the equal pay activist Lilly Ledbetter in this misty-eyed drama. By Beatrice Loayza When you purchase a ticket for an independently reviewed film through our site ...

Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.